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Lung cancer is a leading cause of cancer‐related deaths with an increasing incidence and poor prognoses, due to the lack of knowledge on heterogeneity complexity.[1](#jcmm13782-bib-0001){ref-type="ref"} Systems heterogeneity of lung cancer was described by integrating gene or protein expression, epigenetics, sequencing, transcription or interaction.[2](#jcmm13782-bib-0002){ref-type="ref"} Of those, there are a few studies on the heterogeneity of lipidomic profiles among lung diseases, which play an important role in the development, evolution, metabolism and mechanic function of lung. Marien et al[3](#jcmm13782-bib-0003){ref-type="ref"} investigated cancer and adjunct non‐malignant tissue contents of 91 phospholipid species in patients with small cell lung cancer (SCLC) and found that levels of SMs mainly reduced, while specific PIs elevated in cancer tissues. Reduced levels of PSs were correlated with some of elevated PE and PC species. Main changes were lipids with 40 or 42 carbon atoms in dual fatty acyl chains, with heterogeneity of phospholipids among cancer cells. Intratumour metabolic heterogeneity exists in cancer tissues, e.g renal cancer,[4](#jcmm13782-bib-0004){ref-type="ref"} contributing to the response of cancer cells to therapies. The human plasma lipidome is made up of thousands of ubiquitous lipid species to reflect systemic lipid metabolism and has the clinical relevance of diagnostics with the severity and risk of the disease. Although earlier studies implicated changes of lipid metabolism in tumour tissues,[3](#jcmm13782-bib-0003){ref-type="ref"}, [5](#jcmm13782-bib-0005){ref-type="ref"}, [6](#jcmm13782-bib-0006){ref-type="ref"} there is little known on systematic changes in lipidomic profiles in patients with lung cancer. The aim of our preliminary study is to explore the profiles of plasma lipidome between health and patients with lung cancer or among patients with squamous cell carcinomas (SCC), adenocarcinoma (ADC) or SCLC and to correct lipidomic and genomic profiles.

About 388 lipid molecules of plasma harvested from 8 health and 26 patients with SCC, ADC or SCLC were measured by MRM analysis performed with normal phase HPLC/MS. Patients with lung cancer as the first diagnosis and before any treatment were prospectively recruited at the initial clinic in Fudan University Zhongshan Hospital, without diabetes or other diseases. The study was approved by the Ethical Committee of Zhongshan Hospital. Total lipids were extracted from 200 μL plasma, performed with a modified method of Bligh & Dyer.[7](#jcmm13782-bib-0007){ref-type="ref"} Internal standard cocktails (Avanti Lipids Polar) were added at an amount of 10 μL to each sample, and lipid extracts were subjected to the normal‐phase silica liquid chromatography‐coupled triple‐quadrupole mass spectrometers (Qtrap^®^ 4000 and 6500, Sciex, Framingham, MA, USA). Both negative and positive ESI modes were used, the Q‐Trap was operated in the MRM mode, and different precursor/product ion pairs were scanned. Each experiment was repeated thrice. MRM data were processed with MultiQuant™ software (AB Sciex), and peak area of each pair was used for further quantification. Lung cancer specificity was identified to compare the pooled group of all subtypes with the health. The subtype specificity was defined as the level significantly higher or lower than that in the health (\>twofold and *P* \< 0.05), but not in other subtypes.

It was firstly reported that circulating levels of PS and lysoPS significantly increased, while lysoPE and PE decreased in patients with lung cancer. Our data demonstrated that the circulating levels of PE40s or lysoPE20s lipid species were significantly higher or lower in patients with lung cancer, respectively, of which about 28 lipid species co‐existed in all subtypes of lung cancer. It indicates that the systemic inflammation is in a high reactive condition, where cytokines may interact more with or cross local and systemic leucocytes or tumour cells.[8](#jcmm13782-bib-0008){ref-type="ref"} Lipidome comprehensive characterizations are dependent upon the number of carbon atoms, dual bonds or isomerism in the lipid molecule. For example, PS40:6, lysoPS22:6 or PS34:5 elevated \>100‐fold, PS36:1 or 40:5, or lysoPS18:2 \> 50, as well as PS34:1 or 34:2, lysoPS16:0 or 22:4 \> 20, while d181So and lysoPE20:4(sn‐2) decreased \>10‐fold, lysoPE20:3(sn‐2), 22:6(sn‐1) or 20:5(sn‐1) \>5 and d171So, PS33:1, 33:2,35:4p or lysoPI22:0(sn‐1) \>3. We further map the comprehensively lipidomic profiles and define subtype specificity of lung cancer, by comparing one subtype with healthy or other two subtypes. We noticed that 1 and 51 lipid species in SCC were significantly higher and lower, 34 and 6 in ADC or 5 and 4 in SCLC, respectively. Levels of PG or PI reduced mainly in SCC or ADC, while PS or PE elevated in ADC or SCLC, respectively (Table [1](#jcmm13782-tbl-0001){ref-type="table"}). Figure [1](#jcmm13782-fig-0001){ref-type="fig"} demonstrates the heatmap of lipidomic profiles (Figure [1](#jcmm13782-fig-0001){ref-type="fig"}A), quantitative identification of main lipid elements, e.g PC, PS and PE (Figure [1](#jcmm13782-fig-0001){ref-type="fig"}B) and total levels of PC, PE, PS, SM and PI (Figure [1](#jcmm13782-fig-0001){ref-type="fig"}C) between health and lung cancer subtypes. The principal component analysis indicates the cover area (Figure [1](#jcmm13782-fig-0001){ref-type="fig"}D) and detailed distribution (Figure [1](#jcmm13782-fig-0001){ref-type="fig"}E) of lipidomic profiles in health and patients with various subtypes of lung cancer.

###### 

Up‐ or down‐regulated type‐special lipids in serum over twofold in adenocarcinoma (ADC), squamous cell carcinoma (SCC) or small cell lung cancer (SCLC)

  Lipid symbol                                 Fold          Lipid symbol         Fold
  -------------------------------------------- ------------- -------------------- -------------
  Up‐regulated type‐special lipids in SCC                                         
  PE 34:1                                      2.413927591                        
  Up‐regulated type‐special lipids in ADC                                         
  PS32:1                                       5.09765       lysoPS15:1           11.06539345
  lysoPS20:2                                   17.472675     lysoPS20:1           18.84013333
  PS30:1                                       19.00129722   PS38:6               19.63504722
  lysoPS22:0                                   21.87011944   PS36:3               26.31176111
  PS35:2                                       32.28302361   PS35:1               33.0320804
  lysoPS16:0                                   35.35140556   PS34:0               37.26924167
  PS34:3                                       50.05725958   PS38:5               56.80440113
  PS38:2                                       59.53787133   lysoPS22:4           61.52068609
  lysoPS20:3                                   63.70933056   PS34:2               77.12018239
  lysoPS16:0                                   90.27303933   lysoPS18:2           94.63135557
  PS36:0                                       100.2976925   PS40:4               103.1282059
  PS38:4                                       110.1863088   PS36:1               130.7878593
  PS40:5                                       141.3205679   lysoPS22:6           144.0307609
  PS36:2                                       154.2687604   PS38:3               170.3411736
  PS34:5                                       198.4490358   PS40:6               237.5144428
  lysoPS18:1                                   271.9142996   lysoPS20:4           422.4742472
  PS34:4                                       672.3756202   lysoPS18:0           772.2299397
  Up‐regulated type‐special genes in SCLC                                         
  PC 40:1                                      2.452430888   PC 40:4              3.035423914
  PE 38:1                                      6.919780093   PE 42:7              8.224826755
  PE 40:3                                      12.80649768                        
  Down‐regulated type‐special lipids in ADC                                       
  PI 30:0                                      3.138308237   PI 33:0              2.973606913
  PI 33:1e                                     2.756489035   PI 30:1              2.448825305
  PI 33:2e                                     2.401033111   PI 41:6              2.089884861
  Down‐regulated type‐special lipids in SCC                                       
  lysoPI 18:2 (sn‐1)                           3.174021852   lysoPI 17:0 (sn‐1)   2.686501872
  PG36:2                                       2.599471242   PG35:2               2.599471242
  PG35:3                                       2.582298818   PG35:1               2.573201161
  PG34:0                                       2.571442278   PG39:7               2.57054263
  PG37:3                                       2.568963178   PG35:4               2.560667263
  PG34:1                                       2.544927869   PG36:0               2.540946865
  PG40:1                                       2.533367656   PG37:6               2.519840973
  PG36:1                                       2.517071946   PG33:1               2.509337261
  PG41:6                                       2.508824969   lysoPG19:0           2.502973929
  PG35:5                                       2.498092401   PG38:1               2.493572762
  PG37:4                                       2.478698123   PG38:3               2.467495233
  PG37:2                                       2.466940759   PG32:0               2.459511221
  PG37:5                                       2.457177588   PG34:2               2.454550159
  lysoPG22:4                                   2.445162623   lysoPG20:3           2.436735333
  lysoPG22:0                                   2.414907832   PG40:4               2.412623442
  PG36:4                                       2.411241381   lysoPG20:2           2.395150124
  PG33:2                                       2.394734033   PG38:2               2.390172121
  PG40:5                                       2.37513548    PG36:5               2.355426245
  PG38:4                                       2.350017951   PG34:3               2.344849524
  lysoPG20:4                                   2.321610499   PG31:0               2.318186638
  lysoPG20:5                                   2.302249424   PG36:3               2.297141059
  lysoPG20:0                                   2.296203929   lysoPG18:3           2.239909774
  lysoPG17:0                                   2.238864462   PG40:8               2.236149498
  PG38:6                                       2.231677958   PG38:5               2.21673939
  PG39:3                                       2.163513382   PG40:6               2.162950362
  PG40:7                                       2.139169557                        
  Down‐regulated type‐special lipids in SCLC                                      
  lysoPC 20:5                                  3.679763534   d171S1P              2.622291711
  PE 35:5p                                     2.377716405   Cer120               2.227294449
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![The Heatmap of Lipidomic Profiles (A) was Compared between the Health (as normal) and Patients with Squamous Cell Carcinomas (SCC), Adenocarcinoma (ADC) or Small Cell Lung Cancer (SCLC). The measurement quality of lipidomic profiles was shown by the precursor ion scan of phosphocholine (PC)‐, phosphatidylserine (PS)‐, phosphatidylethanolamine (PE)‐containing phospholipid species in plasma (B). The amounts (nmol lipid/mg DNA) of phospholipid head‐group classes, e.g PC, PE, PS, phosphatidylinositol (PI) or sphingomyelins (SM), were pooled and calculated among the health (as normal) or patients with SCC, ADC or SCLC, as presented in C (\*\*\*\<0.001). Three‐dimensional scatter plots of the principal component scores were illustrated in the validation set based on the weights from the discovery set (D). Component analysis of partial least squares‐discriminant analysis (PLS‐DA) by metabolism between the health (as normal) and patients with SCC, ADC or SCLC was scattered in E](JCMM-22-5155-g001){#jcmm13782-fig-0001}

Our results deliver the significant message that the heterogeneity of lipidomic profiles among lung cancer subtypes should be seriously considered and has the unique value of early diagnostics. For example, PI significantly increased with a decrease in PS in cancer tissues of patients with non‐small cell lung cancer,[3](#jcmm13782-bib-0003){ref-type="ref"} while there are no similar findings in plasma samples of patients with early lung cancer.[9](#jcmm13782-bib-0009){ref-type="ref"} Our present study demonstrated the elevation of PS in patients with lung cancer, as compared with healthy, rather than PI (Figure [1](#jcmm13782-fig-0001){ref-type="fig"}B). Altered PS species in the circulation can be valuable biomarkers to screen the risk population if those PS may be generated from lung cancer cells, or be an early lung cancer‐dependent pattern of lipid metabolism. The reduced amount of multi‐PS species within lung cancer cells can be due to the over‐consumed or over‐metabolized, to the over‐release of cytoplasm into the circulation or to the increased binding and activity of negatively charged lipids PS, PA and PG on lung cancer cell surfaces.[10](#jcmm13782-bib-0010){ref-type="ref"} The changed serum levels of phospholipids and their derivatives, e.g lysophosphatidylcholines and lysophosphatidylethanolamine, are considered as promising cancer markers.[9](#jcmm13782-bib-0009){ref-type="ref"}, [11](#jcmm13782-bib-0011){ref-type="ref"} On basis of previous finding that plasma level of the LPC reduced in patients with lung cancer and colorectal cancer,[12](#jcmm13782-bib-0012){ref-type="ref"} our results furthermore evidenced that lysoPG and lysoPI are lower in the plasma of patients with lung cancer than healthy individuals.

Lipid synthesis and its metabolites were suggested as a metabolic liability and potential biomarkers of lung cancer.[13](#jcmm13782-bib-0013){ref-type="ref"} Lipidome varied between the health and patients with lung cancer or among subtypes implies the existence of lipidomic heterogeneity, which may be caused by local and systemic cell metabolism and inflammation. To further understand the regulatory mechanisms of lipidomic profiles in lung cancer subtypes, we mined the genomic profiles of lipid‐associated enzymes and proteins from the global database integrated the data of large‐scale genome screening and other large mutation databases, as reported previously.[14](#jcmm13782-bib-0014){ref-type="ref"} We found that a large number of lipid protein‐associated genes significantly change among cancer subtypes, with correlations with altered species and spatial structures of lipid metabolites, like ACOT, ACSL, PKD gene families. Most of the long‐chain fatty acids (carbon atoms \> 40) were up‐regulated in lung cancer. The over‐expression of fatty acid synthase (FASN) occurs in cancers, leading to the over‐production of endogenous fatty acids. Acyl‐CoA synthetases (ACSLs) enzymes, which convert free long‐chain fatty acids into fatty acyl‐CoA esters, also participate in the metabolic reprogramming of cancer cells. Recent study showed ACSL3 is the critical element for the oncogenic capacity of mutant KRAS in lung cancer.[15](#jcmm13782-bib-0015){ref-type="ref"}

A number of genes and proteins are suggested as molecular biomarkers or therapeutic targets, which may contribute to the transit process from chronic obstructive pulmonary diseases to lung cancer.[16](#jcmm13782-bib-0016){ref-type="ref"} It is questioned whether lipid species or lipidomic profiles can be identified as stable biomarkers to monitor such transit process. It is also important to define the consistence and correlation of lipidomic profiles with genomic and proteomic ones. Our previous studies demonstrate that it is important and valuable to compare genomics and proteomics, while more important to integrate genomics and proteomics with clinical phenomes.[17](#jcmm13782-bib-0017){ref-type="ref"}, [18](#jcmm13782-bib-0018){ref-type="ref"}, [19](#jcmm13782-bib-0019){ref-type="ref"}, [20](#jcmm13782-bib-0020){ref-type="ref"} It will be a new challenge to merge or fuse lipidomics with clinical phenomics as the part of clinical trans‐omics.[21](#jcmm13782-bib-0021){ref-type="ref"} Thus, our data indicate that lung cancer‐specific and subtype‐specific lipidomics in the circulation are important to understand mechanisms of systemic metabolisms and identify diagnostic biomarkers and therapeutic targets. However, the roles of carbon atoms, dual bonds or isomerism in the lipid molecule in lung cancer cell differentiations should be further explored in future studies.
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